Activity of Brigatinib in Alectinib-Resistant ALK-Positive NSCLC According to ALK Plasma Mutation Status From J-ALTA Trial

被引：0
|
作者：
Hida, T. [1 ]
Katayama, R. [2 ]
Nishio, M. [3 ]
Yoshida, T. [4 ]
Kumagai, T. [5 ]
Toyozawa, R. [6 ]
Shimokawaji, T. [7 ]
Goto, K. [8 ]
Nakagawa, K. [9 ]
Seto, T. [10 ]
Yamamoto, N. [11 ]
Asato, T. [12 ]
Hiraoka, K. [13 ]
Zhang, P. [14 ]
Ohe, Y. [15 ]
机构：
[1] Aichi Canc Ctr, Dept Thorac Oncol, Nagoya, Aichi, Japan
[2] Japanese Fdn Canc Res, Div Expt Chemotherapy, Ctr Canc Chemotherapy, Tokyo, Japan
[3] Japanese Fdn Canc Res, Dept Thorac Med Oncol, Canc Inst Hosp, Tokyo, Japan
[4] Natl Canc Ctr, Thorac Oncol, Tokyo, Japan
[5] Osaka Int Canc Inst, Dept Thorac Oncol, Osaka, Japan
[6] Natl Hosp Org Kyushu Canc Ctr, Fukuoka, Japan
[7] Kanagawa Canc Ctr, Yokohama, Kanagawa, Japan
[8] Natl Canc Ctr Hosp East, Dept Thorac Oncol, Kashiwa, Chiba, Japan
[9] Kindai Univ, Fac Med, Dept Med Oncol, Higashiosaka, Osaka, Japan
[10] NHO Kyushu Canc Ctr, Thorac Oncol, Fukuoka, Japan
[11] Wakayama Med Univ, Wakayama, Japan
[12] Takeda Pharmaceut Co Ltd, Oncol Therapeut Area Unit Japan & Asia, Tokyo, Japan
[13] Takeda Pharmaceut Co Ltd, Japan Oncol Business Unit, Tokyo, Japan
[14] Millennium Pharmaceut Inc, Cambridge, MA USA
[15] Natl Canc Ctr, Tokyo, Japan
来源：
JOURNAL OF THORACIC ONCOLOGY | 2021年 / 16卷 / 03期
关键词：
brigatinib; alectinib-resistant; ALK-positive NSCLC;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P75.01
引用
收藏
页码：S572 / S572
页数：1
相关论文
共 50 条
  • [1] Brigatinib in Japanese Patients With ALK-Positive NSCLC Previously Treated With Alectinib and Other Tyrosine Kinase Inhibitors: Outcomes of the Phase 2 J-ALTA Trial
    Nishio, Makoto
    Yoshida, Tatsuya
    Kumagai, Toru
    Hida, Toyoaki
    Toyozawa, Ryo
    Shimokawaji, Tadasuke
    Goto, Koichi
    Nakagawa, Kazuhiko
    Ohe, Yuichiro
    Seto, Takashi
    Kudou, Kentarou
    Asato, Takayuki
    Zhang, Pingkuan
    Yamamoto, Nobuyuki
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : 452 - 463
  • [2] Brigatinib in Patients With Alectinib-Refractory ALK-Positive NSCLC
    Lin, Jessica J.
    Zhu, Viola W.
    Schoenfeld, Adam J.
    Yeap, Beow Y.
    Saxena, Ashish
    Ferris, Lorin A.
    Dagogo-Jack, Ibiayi
    Farago, Anna F.
    Taber, Angela
    Traynor, Anne
    Menon, Smitha
    Gainor, Justin F.
    Lennerz, Jochen K.
    Plodkowski, Andrew J.
    Digumarthy, Subba R.
    Ignatius, Sai-Hong
    Shaw, Alice T.
    Riely, Gregory J.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : 1530 - 1538
  • [3] Efficacy of Brigatinib in Patients With Advanced ALK-Positive NSCLC Who Progressed on Alectinib or Ceritinib: ALK in Lung Cancer Trial of brigAtinib-2 (ALTA-2)
    Ou, Sai-Hong Ignatius
    Nishio, Makoto
    Ahn, Myung-Ju
    Mok, Tony
    Barlesi, Fabrice
    Zhou, Caicun
    Felip, Enriqueta
    de Marinis, Filippo
    Kim, Sang-We
    Perol, Maurice
    Liu, Geoffrey
    Migliorino, Maria Rita
    Kim, Dong-Wan
    Novello, Silvia
    Bearz, Alessandra
    Garrido, Pilar
    Mazieres, Julien
    Morabito, Alessandro
    Lin, Huamao M.
    Yang, Hui
    Niu, Huifeng
    Zhang, Pingkuan
    Kim, Edward S.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (12) : 1404 - 1414
  • [4] Alectinib in crizotinib-resistant, ALK-positive NSCLC
    Jassem, Jacek
    LANCET ONCOLOGY, 2016, 17 (02): : 134 - 135
  • [5] Activity of brigatinib (BRG) in crizotinib (CRZ)-resistant ALK plus NSCLC patients (pts) according to ALK plasma mutation status.
    Bazhenova, Lyudmila
    Hodgson, J. Graeme
    Langer, Corey J.
    Simon, George R.
    Gettinger, Scott N.
    Ou, Sai-Hong Ignatius
    Reckamp, Karen L.
    West, Howard Jack
    Chiappori, Alberto
    Koh, Han A.
    Molina, Julian R.
    Shaw, Alice Tsang
    Patel, Jyoti D.
    Favaro, Justin Peter
    Haney, Jeff
    Reichmann, William
    Kerstein, David
    Rivera, Victor M.
    Camidge, D. Ross
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [6] The Optimal ALK inhibitor in Advanced ALK-Positive NSCLC Patients: An Indirect Comparison Between Brigatinib and Alectinib
    Chen, G.
    Zhang, Y.
    Zhou, H.
    Zhao, S.
    Liu, J.
    Hong, S.
    Zhang, L.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (12) : S1056 - S1056
  • [7] Brigatinib After Progression From Alectinib or Crizotinib: Paving the Way for Treatment Sequencing of ALK Inhibitors in ALK-Positive NSCLC
    Song, Lianxi
    Xu, Qinqin
    Lizaso, Analyn
    Zhang, Yongchang
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : 349 - 351
  • [8] Brigatinib Versus Alectinib in ALK-Positive NSCLC After Disease Progression on Crizotinib: Results of Phase 3 ALTA-3 Trial
    Yang, James Chih-Hsin
    Liu, Geoffrey
    Lu, Shun
    He, Jianxing
    Burotto, Mauricio
    Ahn, Myung-Ju
    Kim, Dong-Wan
    Liu, Xiaoqing
    Zhao, Yanqiu
    Vincent, Sylvie
    Yin, Jiani
    Ma, Xin
    Lin, Huamao M.
    Popat, Sanjay
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (12) : 1743 - 1755
  • [9] Brigatinib in Japanese patients (pts) with ALK plus NSCLC: Final results from the phase 2 J-ALTA trial.
    Zhang, Pingkuan
    Kumagai, Toru
    Yoshida, Tatsuya
    Nishio, Makoto
    Toyozawa, Ryo
    Seto, Takashi
    Nakagawa, Kazuhiko
    Ohe, Yuichiro
    Yamamoto, Nobuyuki
    Kudou, Kentarou
    Asato, Takayuki
    Goto, Koichi
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [10] Brigatinib in Japanese patients with ALK-positive non-small-cell lung cancer: Final results of the phase 2 J-ALTA trial
    Yoshida, Tatsuya
    Kumagai, Toru
    Toyozawa, Ryo
    Katayama, Ryohei
    Nishio, Makoto
    Seto, Takashi
    Goto, Koichi
    Yamamoto, Nobuyuki
    Ohe, Yuichiro
    Kudou, Kentarou
    Asato, Takayuki
    Zhang, Pingkuan
    Nakagawa, Kazuhiko
    CANCER SCIENCE, 2023, 114 (09) : 3698 - 3707
12345